Inhibition Of Human Tumour Prostate PC-3 Cell Growth

Cannabis and Prostate cancer: There is considerable interest in the application of selective CB2 receptor agonists, which are devoid of typical marijuana-like psychoactive properties of CB1 agonists, for future cannabinoid-based anticancer therapies. This study, done in Spain and published in the British Journal of Cancer in 2009, has findings that point to the potential application of cannabinoid receptor type 2 ligands as anti-tumour agents in prostate cancer.